Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05727943
PHASE2

Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study

Sponsor: KU Leuven

View on ClinicalTrials.gov

Summary

In this exploratory trial, the potential anti-seizure activity of clioquinol in a small cohort of adolescents with drug-resistant epilepsy will be examined. Subjects will be exposed to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose). The main hypothesis of the study is that 30% of the included subjects will be responders and that the median seizure frequency reduction will be at least 30%.

Key Details

Gender

All

Age Range

12 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-03-01

Completion Date

2026-10-01

Last Updated

2026-10-20

Healthy Volunteers

No

Interventions

DRUG

Clioquinol

add on clioquinol to concomitant ASM

Locations (1)

University Hospitals UZ Leuven

Leuven, Belgium